Reviews
31 March 2026
Vol. 4 No. 1 (2026)
Obesity and left atrial function: state of the art
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
34
Views
16
Downloads
Authors
Obesity is an established risk factor for heart failure (HF), with every unit increase in body mass index, the risk of HF increases by 5-7%. Obesity can especially increase the risk for HF with preserved ejection fraction due to left atrial (LA) dysfunction caused by underlying systemic inflammation, chronic volume overload, and growth of epicardial adipose tissue. LA function can be assessed by measuring LA reservoir, conduit and booster, which correspond to physiological functions of LA filling during filling phase of cardiac cycle, LA pushing blood into left ventricle passively, and LA contraction to push the blood into left ventricle, respectively. Existing data show strong prognostic ability of LA strain reservoir for cardiovascular mortality and HF hospitalization. Several studies have also suggested that obesity in itself can cause reduction in LA strain and deterioration of LA function. Whether various weight loss interventions for patients with obesity can minimize and reverse LA remodeling and dysfunction remains unclear. In this review, we summarize the evidence regarding the impact of obesity on LA function, and discuss the impact of various weight reduction techniques on LA strain.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Chopra V, Khan MS, Abdelhamid M, et al. ICARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Glob Cardiol 2025;3:70.
2. Butler J, Shah SJ, Magwire M, et al. Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients. Glob Cardiol 2024;2:38.
3. Aga Y, Kroon D, Snelder S, et al. Decreased left atrial function in obesity patients without known cardiovascular disease. Int J Cardiovasc Imaging 2022:1-9.
4. Anker SD, Ji L, Kindel T, et al. iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025-Focus on prevention and treatment of cardiometabolic disease. Glob Cardiol 2025;3:86.
5. Santos AB, Kraigher-Krainer E, Gupta DK, et al. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014;10:1096-103.
6. Freed BH, Daruwalla V, Cheng JY, et al. Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain. Circ Cardiovasc Imaging 2016;3:e003754.
7. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016;1:73-90.
8. Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;2:93-102.
9. Reddy YN, Lewis GD, Shah SJ, et al. eds. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 2019.
10. Sawada N, Nakanishi K, Daimon M, et al. Independent effect of visceral fat on left atrial phasic function in the general population. Nutr Metab Cardiovasc Dis 2021;12:3426-33.
11. He J, Yang W, Wu W, et al. Clinical features, myocardial strain and tissue characteristics of heart failure with preserved ejection fraction in patients with obesity: a prospective cohort study. Eclinicalmedicine 2023;55:101723.
12. Ancona R, Comenale Pinto S, Caso P, et al. Left atrium by echocardiography in clinical practice: from conventional methods to new echocardiographic techniques. Sci World J 2014;2014:451042.
13. Jia F, Chen A, Zhang D, et al. Prognostic value of left atrial strain in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:935103.
14. Deal O, Rayner J, Stracquadanio A, et al. Effect of weight loss on early left atrial myopathy in people with obesity but no established cardiovascular disease. J Am Heart Assoc 2022;22:e026023.
15. Snelder SM, Aga Y, De Groot-de Laat LE, et al. Cardiac function normalizes 1 year after bariatric surgery in half of the obesity patients with subclinical cardiac dysfunction. Obes Surg 2021;31:4206-9.
16. Mishima RS, Ariyaratnam JP, Pitman BM, et al. Cardiorespiratory fitness, obesity and left atrial function in patients with atrial fibrillation. IJC Heart Vasculature 2022;42:101083.
17. Alfuhied A, Gulsin GS, Athithan L, et al. The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study. Int J Cardiovasc Imaging 2022;9:2013-23.
18. Steele JM, Urbina EM, Mazur WM, et al. Left atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults. Cardiovasc Diabetol 2020;19:1-9.
19. Fang NN, Sui DX, Yu JG, et al. Strain/strain rate imaging of impaired left atrial function in patients with metabolic syndrome. Hypertens Res 2015;38:758-64.
20. Mengozzi A, Masi S, Virdis A. Obesity-related endothelial dysfunction: Moving from classical to emerging mechanisms. Endocr Metab Sci 2020;1:100063.
21. Francis GS, Felker GM, Tang WW. A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 2016;67:330-7.
22. Stavrakis S, Pakala A, Thadani U, et al. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. Am J Med Sci 2013;345:211-7.
23. Singleton MJ, Nelson MB, Samuel TJ, et al. Left atrial stiffness index independently predicts exercise intolerance and quality of life in older, obese patients with heart failure with preserved ejection fraction. J Card Fail 2022;28:567-75.
24. Stritzke J, Markus MRP, Duderstadt S, et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging: the MONICA/KORA study. J Am Coll Cardiol 2009;54:1982-9.
25. Cuspidi C, Negri F, Sala C, et al. Association of left atrial enlargement with left ventricular hypertrophy and diastolic dysfunction: a tissue Doppler study in echocardiographic practice. Blood Press 2012;21:24-30.
26. Cohn JN, Ferrari R, Sharpe N, et al. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
27. Lavie CJ, Pandey A, Lau DH, et al. Obesity and atrial fibrillation: prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol 2017;70:2022-35.
28. Alpert MA, Omran J, Bostick BP. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. Curr Obes Rep 2016;5:424-34.
29. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009;302:401-11.
30. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 2014;10:364-76.
31. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg 2020;9:80.
32. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 2005;91:250-6.
33. Goudis CA, Korantzopoulos P, Ntalas IV, et al. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol 2015;66:361-9.
34. Pandit SV, Anumonwo J, Jalife J. Atrial fibrillation susceptibility in obesity: an excess adiposity and fibrosis complicity? Circ Res 2016;118:1468-71.
35. Kenchaiah S, Ding J, Carr JJ, et al. Pericardial fat and the risk of heart failure. J Am Coll Cardiol 2021;77:2638-52.
36. Patel DA, Lavie CJ, Milani RV, et al. Clinical implications of left atrial enlargement: a review. Ochsner J 2009;9:191-6.
37. Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015;132:691-718.
38. Yamaguchi M, Arakawa M, Tanaka T, et al. Study on left atrial contractile performance: participation of Frank-Starling mechanism. Jpn Circ J 1987;51:1001-9.
39. Garza CA, Pellikka PA, Somers VK, et al. Major weight loss prevents long-term left atrial enlargement in patients with morbid and extreme obesity. Eur J Echocardiogr 2008;9:587-93.
40. Strzelczyk J, Kalinowski P, Zieniewicz K, et al. The influence of surgical weight reduction on left atrial strain. Obes Surg 2021;31:5243-50.
41. Kokkinos A, Alexiadou K, Liaskos C, et al. Improvement in cardiovascular indices after Roux-en-Y gastric bypass or sleeve gastrectomy for morbid obesity. Obes Surg 2013;23:31-8.
42. Sorimachi H, Obokata M, Omote K, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol 2022;80:1501-12.
43. Packer M. Drugs that ameliorate epicardial adipose tissue inflammation may have discordant effects in heart failure with a preserved ejection fraction as compared with a reduced ejection fraction. J Card Fail 2019;25:986-1003.
44. Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012;74:744-56.
45. Soucek F, Covassin N, Singh P, et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol 2015;116:1443-6.
46. Yang Q, Qi X, Dang Y, et al. Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing. BMC Cardiovasc Disord 2016;16:142.
47. Caglayan E, Stauber B, Collins AR, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 2008;57:2470-9.
48. Sacks HS, Fain JN, Cheema P, et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 2011;34:730-3.
49. Grosso AF, de Oliveira SF, Higuchi ML, et al. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr 2014;6:47.
50. Maffioli P, Fogari E, D’Angelo A, et al. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. Eur J Gastroenterol Hepatol 2013;25:1113-22.
51. Chen WJ, Greulich S, van der Meer RW, et al. Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol 2013;12:150.
52. Díaz-Rodríguez E, Agra RM, Fernandez AL, et al. Novel effects of dapagliflozin on epicardial adipose tissue with insulin resistance, high levels of inflammatory chemokines production and low differentiation ability. Cardiovasc Res 2017;114:336-46.
53. Kusaka H, Koibuchi N, Hasegawa Y, et al. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 2016;15:157.
54. Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2017;9:78.
55. Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 2018;17:6.
56. Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016;18:882-91.
57. Iacobellis G, Mohseni M, Bianco SD, et al. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring) 2017;25:311-6.
58. Myasoedova VA, Parisi V, Moschetta D, et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol 2023;22:23.
59. Wong CX, Ganesan AN, Selvanayagam JB. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2016;109:555-62.
60. O'Neill JO, Young JB, Pothier CE, et al. Pharmacokinetics, pharmacodynamics, and drug disposition in obese patients. J Cardiovasc Pharmacol Ther 2012;17:261-8.
61. Voigt JU, Mălăescu GG, Haugaa K, et al. How to do LA strain. Eur Heart J Cardiovasc Imaging 2020;21:715-7.
62. Thomas L, Muraru D, Popescu BA, et al. Evaluation of left atrial size and function: relevance for clinical practice. J Am Soc Echocardiogr 2020;33:934-52.
63. Nagueh SF, Sanborn DY, Oh JK, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography. J Am Soc Echocardiogr 2025;38:537-69.
64. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.
65. Donal E, Galli E, Schnell F. Left atrial strain: a must or a plus for routine clinical practice? Circ Cardiovasc Imaging 2017;10:e007023.
66. Tanasa A, Burlacu A, Popa C, et al. A systematic review on the correlations between left atrial strain and cardiovascular outcomes in chronic kidney disease patients. Diagnostics 2021;11:671.
67. Hummel YM, Liu LC, Lam CS, et al. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail 2017;19:1651-60.
68. Lindqvist P, Henein M. Left atrial strain rate during atrial contraction predicts raised pulmonary capillary wedge pressure: evidence for left atrio-ventricular interaction. Int J Cardiovasc Imaging 2021;37:1529-38.
69. Morris DA, Belyavskiy E, Aravind-Kumar R, et al. Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction. JACC Cardiovasc Imaging 2018;11:1405-15.
70. Fioretti F, Lindman BR, Butler J. Biological plausibility and implications of obesity associated valvular heart diseases. Glob Cardiol 2024;2.
71. Motoki H, Negishi K, Kusunose K, et al. Global left atrial strain in the prediction of sinus rhythm maintenance after catheter ablation for atrial fibrillation. J Am Soc Echocardiogr 2014;27:1184-92.
72. Russo C, Jin Z, Sera F, et al. Left ventricular systolic dysfunction by longitudinal strain is an independent predictor of incident atrial fibrillation: a community-based cohort study. Circ Cardiovasc Imaging 2015;8:e003520.
73. Cameli M, Mandoli GE, Lisi E, et al. Left atrial, ventricular and atrio-ventricular strain in patients with subclinical heart dysfunction. Int J Cardiovasc Imaging 2019;35:249-58.
74. Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document. Eur Heart J Cardiovasc Imaging 2018;19:591-600.
75. Pathan F, D’Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr 2017;30:59-70.e8.
76. Mohseni-Badalabadi R, Mirjalili T, Jalali A, et al. A systematic review and meta-analysis of the normal reference value of the longitudinal left atrial strain by three dimensional speckle tracking echocardiography. Sci Rep 2022;12.
77. Raman B, Smillie RW, Mahmod M, et al. Incremental value of left atrial booster and reservoir strain in predicting atrial fibrillation in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2021;23:109.
78. Pinto FJ, Anker SD, Abraham WT, et al. The global implementation guidelines initiative: how to optimize cardio-renal-metabolic care worldwide. Glob Cardiol 2025;3:68.
79. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications. J Am Soc Echocardiogr 2011;24:277-313.
How to Cite
1.
Rashid AM, Khan MS, Alenezi F, Anker SD, Knebel F. Obesity and left atrial function: state of the art. Global Cardiol [Internet]. 2026 Mar. 31 [cited 2026 Apr. 17];4(1). Available from: https://www.globalcardiology.info/site/article/view/96
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
